EP Patent

EP3400021A1 — Controlled-release cnp agonists with low npr-c binding

Assigned to Ascendis Pharma Endocrinology Division AS · Expires 2018-11-14 · 8y expired

What this patent protects

The present invention relates to a controlled-release CNP agonist having low NPR-C affinity; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.

USPTO Abstract

The present invention relates to a controlled-release CNP agonist having low NPR-C affinity; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.

Drugs covered by this patent

Patent Metadata

Patent number: EP3400021A1
Jurisdiction: EP
Classification: —
Expires: 2018-11-14
Drug substance claim: No
Drug product claim: No
Assignee: Ascendis Pharma Endocrinology Division AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.